hosphorus is an important element for normal physiologic functions such as bone construction, nerve function, and muscle contraction. About 85% of phosphorus is stored in the bones and different tissues in the body. The excess phosphorus is eliminated from the body by the urinary system. The normal phosphate level in the blood is 3-4 mg/dL. Electrolytic disturbance resulting in high levels of phosphate in the blood causes hyperphosphatemia. Individuals with chronic kidney diseases have a decreased glomerular filtration rate and increased serum phosphate levels. The high phosphate levels in the serum lower calcium levels because of phosphate precipitation by calcium ions, leading to calcification of vascular tissues and heart diseases. Aluminum-, calcium-, magnesium-, and iron-based and aluminum-free, calcium-free phosphate binders are used to treat the condition.
Major factors driving the market include rise in prevalence of chronic diseases, high unmet medical needs, increase in the number of people undergoing dialysis, large geriatric population, and surge in public awareness worldwide. Diabetes and hypertension are the main causes of renal failure, which leads to hyperphosphatemia. However, stringent regulations by regulatory bodies such as the Food and Drug Administration (FDA), non-adherence to treatment regimens, and rise in side effects of hyperphosphatemia drugs are likely to inhibit the market. According to FDA use of hyperphosphatemia drugs for the treatment of high or low phosphorus levels in the human body is neither safe nor effective. High growth potential in untapped economies, such as India, China, South Africa, and Brazil, is expected to create lucrative opportunities for key players. Rise in geriatric population and increase in cases of osteoporosis in Asia Pacific is anticipated to drive the market. Osteoporosis is often undertreated and underdiagnosed, which is driving the hyperphosphatemia drugs market in Asia Pacific. The available calcium, lanthanum, sevelamer, and iron-based drugs for treating hyperphosphatemia are associated with certain side effects. The long-term use of calcium-based drugs such as calcium carbonate and calcium acetate can cause vascular calcification.
The report outlines the development of diverse regions and countries by including the market size, volume and value. It also contains the manufacturers data such as batch, price revenue, profit, interview record and business distributors.
The Hyperphosphatemia Drugs market size was xxx million USD with a CAGR xx % from 2015- 2019. It will stretch to xxx million USD in 2020 with a CAGR of xx % from 2020 to 2025.
in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.
In global market, the following companies are covered:
Keryx Biopharmaceuticals
Sanofi
Shire
Vifor Pharma
Amgen
Bayer
...
Market Segment by Product Type:
Aluminum Phosphate Binder
Iron Phosphate Binder
Magnesium Phosphate Binder
Calcium Phosphate Binder
Market Segment by Application
Hospitals
Clinics
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
Apart from the drivers, restraints, and opportunities, the report also offers competitive landscape, including various growth strategies adopted by profiled players for establishing significant position in the industry. The segmentation included in the comprehensive report will help respectable manufacturers to set up their processing units in the regions and increase their global presence. This would also benefit the industry and increase the companys product portfolio.
The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Hyperphosphatemia Drugs market for the forecast period 2020 - 2025?
• What are the driving forces in the Hyperphosphatemia Drugs market for the forecast period 2020 - 2025?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Hyperphosphatemia Drugs industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?